Our seamless tech transfer from pilot plant to commercial scale delivers a structured, risk-based framework to translate validated bioprocess knowledge generated at pilot scale into stable, reproducible commercial manufacturing operations, eliminating the common discontinuities that compromise critical quality attributes, extend CMC timelines and create regulatory exposure. Designed for all biologic classes including monoclonal antibodies, viral vectors, cell therapy intermediates, vaccines and recombinant proteins, this service anchors every transfer activity to the established process understanding, control strategy and design space defined during pilot characterization. We initiate engagement with a comprehensive gap analysis covering equipment geometry, mass transfer regimes, raw material supply chains, analytical methods, operator workflows, environmental controls and data governance, mapping all scale-dependent variables before physical implementation. This foundational alignment ensures that the commercial process inherits the proven performance boundaries of the pilot, rather than treating scale-up as a discrete re-development exercise.
Our technical transfer methodology integrates formal process scale-up science, comparative equipment qualification, analytical method bridging and harmonized control philosophy under a unified master tech transfer plan. We quantify scale-up criteria for core unit operations including bioreactor cultivation, clarification, chromatography, TFF, formulation and fill-finish, establishing justified correlations for mixing time, shear exposure, oxygen transfer coefficient, residence time distribution and impurity clearance. The scope extends to the harmonization of SOPs, batch records, sampling strategies, PAT setpoints and alert limits, alongside coordinated change control and validation planning compliant with ICH, FDA and EU GMP expectations. We facilitate cross-site knowledge exchange between pilot development teams and commercial manufacturing operations, while generating traceable documentation packages that directly support process validation activities and regulatory inspection readiness.
This rigorous, end-to-end transfer model mitigates the financial and schedule risks inherent in scaling biologic processes, reducing the likelihood of costly failed commercial batches, unplanned rework and delayed clinical or commercial supply. By embedding comparative performance verification and bridging studies into the transfer workflow, we confirm that the commercial process maintains equivalent impurity profiles, product potency, aggregation levels and all predefined critical quality attributes. The structured knowledge capture removes reliance on tacit operator know‑how, builds operational confidence at the commercial site and shortens the performance qualification cycle. Whether transferring onto stainless‑steel process trains, single‑use platforms or hybrid configurations, the framework preserves process flexibility and enables rapid campaign execution after handover.
We sustain close collaboration with sponsor development, quality, regulatory and manufacturing teams through every phase, from pre-transfer readiness assessment and protocol drafting, through parallel run bridging, process confirmation and post-transfer performance surveillance. Our cross-functional team of bioprocess scale-up specialists, validation leads and regulatory advisors remains engaged to resolve deviations, refine control parameters and document sustained process performance after the first successful commercial batches. Whether the destination is a newly constructed greenfield facility, a retrofitted brownfield site or a third-party CDMO manufacturing line, our tech transfer approach turns pilot-scale process insight into dependable commercial production, accelerating patient supply while maintaining robust, defensible regulatory compliance.
